Diagnostic values of biomarkers in acute exacerbation of chronic obstructive pulmonary disease
https://doi.org/10.18093/0869-0189-2014-0-4-100-104
Abstract
An acute exacerbation of chronic obstructive pulmonary disease (COPD) plays an important role in the disease progression and significantly reduces the patients' quality of life. The aim of this review was to summarize published findings about a possible role of biomarkers in diagnosis, management and predicting outcomes in COPD patients. Creactive protein and serum amyloid A are the most investigated biomarkers in this field. Measurement of copeptin and proadrenomedullin may be useful in predicting shortterm outcomes. Biomarkeroriented management of patients with acute exacerbation of COPD could be important for choosing medications.
About the Authors
A. V. Budnevskiy
State Institution N.N.Burdenko Voronezh Medical Academy, Healthcare Ministry
Russian Federation
Russian Federation
E. S. Ovsyannikov
State Institution N.N.Burdenko Voronezh Medical Academy, Healthcare Ministry
Russian Federation
Russian Federation
A. V. Chernov
State Institution N.N.Burdenko Voronezh Medical Academy, Healthcare Ministry
Russian Federation
Russian Federation
E. S. Drobysheva
State Institution N.N.Burdenko Voronezh Medical Academy, Healthcare Ministry
Russian Federation
Russian Federation
References
1. Белевский А.С., ред. Глобальная стратегия диагностики, лечения и профилактики хронической обструктивной болезни легких (пересмотр 2011 г.): Пер. с англ. М.: Российское респираторное общество; 2012. / Belevskiy A.S., ed. Global Strategy on Diagnosis, Treatment and Prevention of Chronic Obstructive Pulmonary Disease (revision of 2011). [Global'naya strategiya diagnostiki, lecheniya i profilaktiki khronicheskoy obstruktivnoy boleznilegkikh (peresmotr 2011 g.): Translated from English. Moscow: Rossiyskoe respiratornoe obshchestvo; 2012 (in Russian).
2. Будневский А.В., Прозорова Г.Г., Бурлачук В.Т. и др. Возможности комбинированной терапии при тяжелой хронической обструктивной болезни легких. Атмосфера. Пульмонология и аллергология. 2010; 4: 34–38. / Budnevskiy A.V., Prozorova G.G., Burlachuk V.T. et al. Opportunities of combined therapy of severe chronic obstructive pulmonary disease. Atmosfera. Pul'monologiya i allergologiya. 2010; 4: 34–38 (in Russian).
3. Волкорезов И.А., Будневский А.В., Прозорова Г.Г. Системный анализ клинического течения хронической обструктивной болезни легких у больных с остеопорозом. Вестник новых медицинских технологий. 2010; 1: 29–31. / Volkorezov I.A., Budnevskiy A.V., Prozorova G.G. Systemic analysis of clinical course of chronic obstructive pulmonary disease in patients with osteoporosis. Vestnik novykh meditsinskikh tekhnologiy. 2010; 1: 29–31 (in Russian).
4. Будневский А.В., Трибунцева Л.В., Яковлев В.Н. и др. Оптимизация амбулаторнополиклинической помощи больным хронической обструктивной болезнью легких. Системный анализ и управление в биомедицинских системах. 2012; 2: 464–468. / Budnevskiy A.V., Tribuntseva L.V., Yakovlev V.N. et al. Improvement of ambulatory care of patients with chronic obstructive pulmonary disease. Sistemnyy analiz i upravlenie v biomeditsinskikh sistemakh. 2012; 2: 464–468 (in Russian).
5. Пашкова О.В., Разворотнев А.В., Будневский А.В., Лука'шев В.О. Модель клинического течения хронической обструктивной болезни легких. Системный анализ и управление в биомедицинских системах. 2010; 1: 209–213. / Pashkova O.V., Razvorotnev A.V., Budnevskiy A.V., Lukashev V.O. A model of clinical course of chronic obstructive pulmonary disease. Sistemnyy analiz i upravlenie v biomeditsinskikh sistemakh. 2010; 1: 209–213 (in Russian).
6. Agusti A., Calverley P.M., Celli B. et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir. Res. 2010; 11: 122.
7. Agusti A., Sobradillo P., Celli B. Addressing the complexity of chronic obstructive pulmonary disease: from phenotypes and biomarkers to scalefree networks, systems biology, and medicine. Am. J. Respir. Crit. Care Med. 2011; 183: 1129–1137.
8. Woodruff P.G. Novel outcomes and end points: biomarkers in chronic obstructive pulmonary disease clinical trials. Proc. Am. Thorac. Soc. 2011; 8: 350–355.
9. Sin D.D., Vestbo J. Biomarkers in chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2009; 6: 543–545.
10. Han M.K., Agusti A., Calverley P.M. et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am. J. Respir. Crit. Care Med. 2010; 182: 598–604.
11. Stolz D., Christ'Crain M., Morgenthaler N.G. et al. Copeptin, C reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest. 2007; 131: 1058–1067.
12. Koutsokera A., Kiropoulos T.S., Nikoulis D.J. et al. Clinical, functional and biochemical changes during recovery from COPD exacerbations. Respir. Med. 2009; 103: 919–926.
13. Krommidas G., Kostikas K., Papatheodorou G. et al. Plasmleptin and adiponectin in COPD exacerbations: associations with inflammatory biomarkers. Respir. Med. 2010; 104: 40–46.
14. Markoulaki D., Kostikas K., Papatheodorou G. et al. Hemoglobin, erythropoietin and systemic inflammation in exacerbations of chronic obstructive pulmonary disease. Eur. J. Intern. Med. 2011; 22: 103–107.
15. Tkacova R., Kluchova Z., Joppa P. et al. Systemic inflammation and systemic oxidative stress in patients with acute exacerbations of COPD. Respir. Med. 2007; 101: 1670–1676.
16. Pinto'Plata V.M., Livnat G., Girish M. et al. Systemic cytokines, clinical and physiological changes in patients hospitalized for exacerbation of COPD. Chest. 2007; 131: 37–43.
17. Hurst J.R., Donaldson G.C., Perera W.R. et al. Use of plasmabiomarkers at exacerbation of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2006; 174: 867–874.
18. Bafadhel M., Clark T.W., Reid C. et al. Procalcitonin and Creactive protein in hospitalized adult patients with communityacquired pneumonia or exacerbation of asthma or COPD. Chest. 2011; 139: 1410–1418.
19. Bozinovski S., Hutchinson A., Thompson M. et al. Serum amyloid is a biomarker of acute exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. CareMed. 2008; 177: 269–278.
20. Gariani K., Delabays A., Perneger T.V. et al. Use of brain natriuretic peptide to detect previously unknown left ventricular dysfunction in patients with acute exacerbation of chronic obstructive pulmonary disease. Swiss. Med. Wkly. 2011; 141: 298.
21. Daniels J.M., Schoorl M., Snijders D. et al. Procalcitonin vs C reactive protein as predictive markers of response to antibiotic therapy in acute exacerbations of COPD. Chest. 2010; 138: 1108–1115.
22. Quint J.K., Donaldson G.C., Goldring J.J. et al. Serum IP10 as a biomarker of human rhinovirus infection at exacerbation of COPD. Chest. 2010; 137: 812–822.
23. Bafadhel M., McKenna S., Terry S. et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am. J. Respir. Crit. Care Med. 2011; 184: 662–671.
24. Stolz D., Christ'Crain M., Morgenthaler N.G. et al. Plasma proadrenomedullin but not plasma proendothelin predicts survival in exacerbations of COPD. Chest. 2008; 134: 263–272.
25. Giron R., Matesanz C., Garcia'Rio F. et al. Nutritional state during COPD exacerbation: clinical and prognostic implications. Ann. Nutr. Metab. 2009; 54: 52–58.
26. Martins C.S., Rodrigues M.J., Miranda V.P. et al. Prognostic value of cardiac troponin I in patients with COPD acute exacerbation. Neth. J. Med. 2009; 67: 341–349.
27. Stolz D., Breidthardt T., Christ'Crain M., et al. Use of Btype natriuretic peptide in the risk stratification of acute exacerbations of COPD. Chest. 2008; 133: 1088–1094.
28. Perera W.R., Hurst J.R., Wilkinson T.M. et al. Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur. Respir. J. 2007; 29: 527–534.
29. Chang C.L., Robinson S.C., Mills G.D. et al. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax. 2011; 66: 764–768.
30. Wood'Baker R., Walters J., Walters E.H. Systemic corticos teroids in chronic obstructive pulmonary disease: an overview of Cochrane systematic reviews. Respir. Med. 2007; 101: 371–377.
31. Stolz D., Christ'Crain M., Bingisser R. et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitoninguidance with standard therapy. Chest. 2007; 131: 9–19.
32. Schuetz P., Christ'Crain M., Thomann R. et al. Effect of procalcitoninbased guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. J.A.M.A. 2009; 302: 1059–1066.
33. Daniels J.M., Snijders D., de Graaff C.S. et al. Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2010; 181: 150–157.
34. Kostikas K., Minas M., Papaioannou A.I. et al. Exhaled nitricoxide in asthma in adults: the end is the beginning? Curr. Med. Chem. 2011; 18: 1423–1431.
35. Siva R., Green R.H., Brightling C.E. et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur. Respir. J. 2007; 29: 906–913.
36. Bafadhel M., McKenna S., Terry S. et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo controlled trial. Am. J. Respir. Crit. Care Med. 2012; 186: 48–55.
Review
For citations:
Budnevskiy A.V., Ovsyannikov E.S., Chernov A.V., Drobysheva E.S. Diagnostic values of biomarkers in acute exacerbation of chronic obstructive pulmonary disease. PULMONOLOGIYA. 2014;(4):100-104. (In Russ.) https://doi.org/10.18093/0869-0189-2014-0-4-100-104
Views:
1856
Email this article 